Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using circulating tumor cells (CTCs) in the prognosis of patients with newly diagnosed multiple myeloma (NDMM), highlighting the benefits of this approach over standard bone marrow assessments. Dr Paiva further comments on the feasibility and high reproducibility of this approach. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.